Edgar Filing: MARSHALL & ILSLEY CORP - Form 424B3

MARSHALL & ILSLEY CORP Form 424B3 March 11, 2008

The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus supplement and prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

## SUBJECT TO COMPLETION, DATED MARCH 10, 2008

Marshall & Ilsley Corporation MiNotes

#### PRELIMINARY PRICING SUPPLEMENT

Preliminary Pricing Supplement Dated: 3/10/2008 Rule 424(b)(3)

(To Prospectus Supplement Dated January 23, 2008 File No. 333-147162

and Prospectus Dated November 6, 2007)

Pricing Supplement No. 009

U.S. \$ 500,000,000

# MARSHALL & ILSLEY CORPORATION

### **MINOTES**<sup>SM</sup>

## DUE NINE MONTHS OR MORE FROM DATE OF ISSUE

Trade Date: <u>3/17/2008</u>

Issue Date: 3/20/2008

Agents: Merrill Lynch, Pierce, Fenner & Smith Inc.; Citigroup Global Markets, Inc.; Edward D. Jones & Co, L.P.; InCapital LLC; Morgan Stanley & Co. Incorporated; UBS Securities LLC; Wachovia Capital Markets, LLC

# Edgar Filing: MARSHALL & ILSLEY CORP - Form 424B3

CUSIP	AGGREGATE	PRICE	CONCESSION	NET	SENIOR OR SUB- INTEREST	
	PRINCIPAL AMOUNT	TO PUBLIC		PROCEEDS	ORDINATED	RATE
				TO ISSUER		
57183WAF5	TBD	100.000%	2.5%	TBD	Senior	6.25%

<b>INTEREST</b>	FIRST	<b>MATURITY</b>	SURVIVOR S	S REDEMPTION OR	REDEMPTION/
<b>PAYMENT</b>			OPTION	REPAYMENT	REPAYMENT
FREQUENCY	COUPON	DATE			<b>TERMS</b>
				YES/NO	
	DATE				
Quarterly	6/20/08	3/20/28	Yes	Yes	See below

Option Redemption: The MiNotes will be subject to redemption at the option of Marshall & Ilsley Corporation, on the Interest Payment Date occurring on March 22, 2010 (*rolls on 20<sup>th</sup>*) and on each Interest Payment Date thereafter at a redemption price equal to 100% of the principal amount of the MiNotes, plus any accrued and unpaid interest thereon. See Description of Notes Redemption and Repayment in the prospectus supplement referred to above.